Cargando…

Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up

Tyrosine kinase inhibitors have dramatically improved the prognosis of metastatic renal cell carcinoma (RCC). However, it remains unknown whether treatment should be continued until progression or discontinued in patients with good response. We present the history of a woman diagnosed with RCC in 19...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guerin, Mathilde, Salem, Naji, Walz, Jochen, Dermeche, Slimane, Gravis, Gwenaelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851250/ https://www.ncbi.nlm.nih.gov/pubmed/24073932 http://dx.doi.org/10.1186/1477-7819-11-243

Ejemplares similares

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma
por: Billon, Emilien, et al.
Publicado: (2019)

Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review
por: Rony, Maelle, et al.
Publicado: (2021)

Corrigendum: Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review
por: Rony, Maelle, et al.
Publicado: (2021)

Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report
por: Mari, Roxane, et al.
Publicado: (2022)

Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer
por: Pasero, Christine, et al.
Publicado: (2015)

Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study
por: Chanez, Brice, et al.
Publicado: (2021)

Advance Approval of Outpatient Chemotherapy via Phone Call Optimizes Healthcare Delivery without Compromising Patient Satisfaction with Care
por: Marino, Patricia, et al.
Publicado: (2021)

Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma
por: Billon, Emilien, et al.
Publicado: (2021)

Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial
por: Eisen, Tim, et al.
Publicado: (2008)

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review
por: Rochigneux, Philippe, et al.
Publicado: (2018)

Impact of active surveillance for prostate cancer on the risk of depression and anxiety
por: Sypre, Davidson, et al.
Publicado: (2022)

Transhiatal esophagectomy as a treatment for locally advanced adenocarcinoma of the gastroesophageal junction: postoperative and oncologic results of a single-center cohort: THE for locally advanced GEJC
por: Meillat, Hélène, et al.
Publicado: (2022)

Correction to: Transhiatal esophagectomy as a treatment for locally advanced adenocarcinoma of the gastroesophageal junction: postoperative and oncologic results of a single-center cohort: THE for locally advanced GEJC
por: Meillat, Hélène, et al.
Publicado: (2022)

Systemic treatment for metastatic prostate cancer
por: Gravis, Gwenaelle
Publicado: (2019)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

Therapeutic effect and adverse reaction of sorafenib in the treatment of advanced renal cancer
por: Qiu, Juhui, et al.
Publicado: (2019)

The Psychological Distress of Cancer Patients following the COVID-19 Pandemic First Lockdown: Results from a Large French Survey
por: Marino, Patricia, et al.
Publicado: (2022)

Hepatocellular Carcinoma in a Noncirrhotic Liver after Long-Term Use of Danazol for Hereditary Angioedema
por: Rahal, Soraya, et al.
Publicado: (2014)

Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib
por: Choi, Joon-Il, et al.
Publicado: (2014)

Renal cell carcinoma and the use of sorafenib
por: Larkin, James MG, et al.
Publicado: (2006)

Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment
por: Tatsugami, Katsunori, et al.
Publicado: (2018)

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma
por: Jobard, Elodie, et al.
Publicado: (2015)

Long-term follow-up of complete remission in a patient with advanced hepatocellular carcinoma treated with sorafenib: a case report
por: Adžić, Gordan, et al.
Publicado: (2023)

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
por: Larkin, J M G, et al.
Publicado: (2010)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)

Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?
por: Anastay, Vassili, et al.
Publicado: (2023)

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
por: Coppin, Chris
Publicado: (2010)

Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer()()
por: Choi, Kyung Hwa, et al.
Publicado: (2018)

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
por: Vano, Yann-Alexandre, et al.
Publicado: (2021)

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
por: Sigrand, Julie, et al.
Publicado: (2016)

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
por: Zhu, Qiankun, et al.
Publicado: (2020)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial
por: Billon, Emilien, et al.
Publicado: (2022)

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib
por: Di Fiore, F, et al.
Publicado: (2011)

The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma
por: Qin, Chao, et al.
Publicado: (2016)

14.4 FOLLOW-UP TREATMENT FOR INDIVIDUALS WITH SERIOUS MENTAL ILLNESS WHO HAVE COMMITTED MAJOR CRIMES
por: Torrey, E Fuller
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qvvj65tc4bmcnn9vvblstq9sfu